Drug intelligence / Profile preview

GDC-229

Development stage: Phase 3
Lead developer: Balmoral Medical
Modality: Small Molecules
Administration: Vaginal

Overview

GDC-229 is an investigational vaginal gel formulation containing 0.75% metronidazole, developed by Balmoral Medical for the treatment of bacterial vaginosis. Metronidazole is a nitroimidazole antimicrobial that acts by inhibiting nucleic acid synthesis in anaerobic bacteria, which are the primary pathogens involved in bacterial vaginosis. GDC-229 was evaluated in a Phase 3 clinical trial (NCT03091777) to demonstrate therapeutic equivalence to the FDA-approved reference metronidazole 0.75% vaginal gel and superiority over placebo in female patients.

Other names: metronidazole 0.75% vaginal gel

Targets

NeuraminidaseRNAP (Bacterial dna-dependent RNA polymerase)

Beyond the preview

Go deeper on GDC-229.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GDC-229.

Explore the full profile